Loading patent…
AssigneesThe Asan Foundation, University of Ulsan Foundation for Industry Cooperation, Cbsbioscience Co., Ltd
InventorsChang-Sik YU, In-Ja PARK, Seung-Mo HONG, Sung-Min AHN, Adnan Ahmad ANSARI, Bilal MUSTAFA, Jin-Young PARK
Estimating the term…
Provided are an analytical method of providing an information for diagnosis of a patient who exhibits a response to preoperative chemoradiotherapy in a rectal cancer patient, wherein the expression levels of nine genes, i.e., FGFR3, GNA11, H3F3A, IL12A, IL1R1, IL2RB, NKD1, SGK2, and SPRY2 genes, is analyzed in combination, in carcinoma tissues of a rectal cancer patient, the response (susceptibility) to preoperative chemoradiotherapy can be predicted with high accuracy, and therefore the combination of said genes can be usefully applied as a biomarker for selecting a rectal cancer patient who exhibits a response to preoperative chemoradiotherapy.
An analytical method of providing an information for diagnosis of a patient who exhibits a response to preoperative chemoradiotherapy in a rectal cancer patient, the method of which comprises measuring expression levels of FGFR3, GNA11, H3F3A, IL12A, IL1R1, IL2RB, NKD1, SGK2, and SPRY2 genes, in carcinoma tissue samples which are externally discharged from the rectal cancer patient, respectively.
Dependencies are inferred from the claim text.